Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study

Vaccine

Volumn 32, Issue 44, 2014, Pages 5845-5853

  Laprise, Jean François ^a   Drolet, Mélanie ^a,b   Boily, Marie Claude ^c   Jit, Mark ^d,e   Sauvageau, Chantal ^a   Franco, Eduardo L ^f   Lemieux Mellouki, Philippe ^a,b   Malagón, Talía ^a,b   Brisson, Marc ^a,b,c  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Anogenital warts; Cervical cancer; Cost effectiveness; Human papillomavirus (HPV); Immunisation; Programme optimisation; Transmission dynamic modelling; Vaccine schedules

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANADA; CANCER IMMUNIZATION; CANCER PREVENTION; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROSS PROTECTION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; MALE; MEN WHO HAVE SEX WITH MEN; NONHUMAN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT DURATION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VAGINA CANCER; VULVA CANCER; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; STATISTICAL MODEL;

CANADA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84908086008     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.099     Document Type: Article

References (61)

1. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30(Suppl. 5):F139-F148.
2. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
3. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124(7):1626-1636.
4. Backes D.M., Kurman R.J., Pimenta J.M., Smith J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009, 20(4):449-457.
5. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 2005, 14(2):467-475.
6. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199(6):805-814.
7. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
8. Van de Velde N., Boily M.C., Drolet M., Franco E.L., Mayrand M.H., Kliewer E.V., et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012, 104(22):1712-1723.
9. Brisson M., Van de Velde N., Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12(5-6):343-351.
10. Kim J.J., Brisson M., Edmunds W.J., Goldie S.J. Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(Suppl. 10):K76-K86.
11. Canfell K., Chesson H., Kulasingam S.L., Berkhof J., Diaz M., Kim J.J. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012, 30(Suppl. 5):F157-F167.
12. BC Center for Disease Control Immunization in British Colombia 2008, Available from: http://www.bccdc.ca/NR/rdonlyres/4F2E7994-8A4A-4F2E-9E3E-FFFB7BAD0B1E/0/2008AnnualReportFINALcolour28OCT2010.pdf [accessed June 2013].
13. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
14. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309(17):1793-1802.
15. Kahn J.A., Bernstein D.I. HPV vaccination: too soon for 2 doses?. JAMA 2013, 309(17):1832-1834.
16. Jit M., Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011, 29(5):371-386.
17. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(33):5473-5484.
18. Brisson M., Van de Velde N., Drolet M., Boily M.C., Franco E.L., Mayrand M.H., et al. HPV-advise: technical appendix. J Natl Cancer Inst 2012, http://www.marc-brisson.net/HPVadvise.pdf. 10.1093/jnci/djs395.
19. Pitman R., Fisman D., Zaric G.S., Postma M., Kretzschmar M., Edmunds J., et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Mak 2012, 32(5):712-721.
20. WHO Investing in health for economic development. Report of the Commission on Macroeconomics and Health, Geneva, Switzerland 2001.
21. WHO WHO-CHOICE. World Health Organization statistical information system: choosing interventions that are cost effective 2006.
22. Department of Health UK, Public Health England HPV vaccination programme: HPV annual survey 2011-2012 2012, Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244479/HPV_AnnualVaccineUptake2011-2012.pdf [accessed 30.10.13].
23. Department of Health Australian Government Immunise Australia Program: human papillomavirus (HPV) 2013, Available from: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv [accessed 30.10.13].
24. Ministère de la Santé et des Services Sociaux du Québec (MSSS) Vigie - Interventions: Couverture vaccinale en milieu scolaire. Flash Vigie: Bull qué vigie d'interv mal infect 2010, 5(3):1-2.
25. Drolet M., Brisson M., Maunsell E., Franco E.L., Coutlée F., Ferenczy A., et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2012, 21(10):1071-1081.
26. Drolet M., Brisson M., Maunsell E., Franco E.L., Coutlée F., Ferenczy A., et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011, 38(10):949-956.
27. Statistics Canada Canadian Community Health Survey (CCHS - Cycle 3.1) 2005, Available from: www.statcan.gc.ca [accessed January 2011].
28. Demers A., Kliewer E.V., Musto G., Butler J., Elliot L., Shearer B., et al. Epidemiology of cervical abnormalities and utilization of related health care resources 2009, Cancer Care Manitoba, Winnipeg.
29. Ades S., Koushik A., Duarte-Franco E., Mansour N., Arseneau J., Provencher D., et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 2008, 122(12):2820-2826.
30. Richardson H., Kelsall G., Tellier P., Voyer H., Abrahamowicz M., Ferenczy A., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomark Prev 2003, 12(6):485-490.
31. Mayrand M.H., Duarte-Franco E., Coutlee F., Rodrigues I., Walter S.D., Ratnam S., et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006, 119(3):615-623.
32. Coutlee F., Ratnam S., Ramanakumar A.V., Insinga R.R., Bentley J., Escott N., et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011, 83(6):1034-1041.
33. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128(4):927-935.
34. Liu S., Semenciw R., Probert A., Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001, 11(1):24-31.
35. Public Health Agency of Canada. Cancer surveillance on-line. Available from: [accessed January 2011]. http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cancer/index-eng.php.
36. BC Cancer Agency Cervical cancer screening program. 2009 annual report, Vancouver, BC 2009, Available from: http://www.bccancer.bc.ca [accessed January 2011].
37. Kliewer E.V., Demers A.A., Elliott L., Lotocki R., Butler J.R., Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009, 36(6):380-386.
38. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789.
39. Naud P. Sustained immunogenicity and efficacy of the HPV-16/18 vaccine in women aged 15-25 years: follow-up to 9.4 years. Abstract presented at the 27th International Papillomavirus Conference and Clinical Workshop 2011, 17-21.
40. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36(6):778-792.
41. Institute of Medicine of the National Academies Vaccines for the 21st century: a tool for decision making 1999, Available from: http://www.iom.edu/Reports/1999/Vaccines-for-the-21st-Century-A-Tool-for-Decisionmaking.aspx.
42. Rogers S.N., Miller R.D., Ali K., Minhas A.B., Williams H.F., Lowe D. Patients' perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 2006, 35(10):913-919.
43. Brisson M., Van de Velde N., De Wals P., Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25(29):5399-5408.
44. Anonychuk A.M., Bauch C.T., Merid M.F., Van Kriekinge G., Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009, 9:401.
45. Vijayaraghavan A., Efrusy M.B., Mayrand M.H., Santas C.C., Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec: Canada. Can J Public Health 2010, 101(3):220-225.
46. Kulasingam S.L., Rajan R., St Pierre Y., Atwood C.V., Myers E.R., Franco E.L. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med 2009, 7:69.
47. Marra F., Ogilvie G., Colley L., Kliewer E., Marra C.A. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009, 85(2):111-115.
48. Benedet J.L., Bertrand M.A., Matisic J.M., Garner D. Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada. J Low Genit Tract Dis 2005, 9(3):160-166.
49. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(46):8443-8450.
50. Elbasha E.H., Dasbach E.J. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28(42):6858-6867.
51. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
52. Olsen J., Jepsen M.R. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010, 26(2):183-191.
53. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(11):1915-1923.
54. Comité sur l'immunisation du Québec (CIQ) et Comité scientifique ad hoc VPH La Vaccination contre les VPH au Québec: Mise à jour des connaissances et propositions du comité d'experts. Direction des risques biologiques et de la santé au travail 2012, Institut national de santé publique Québec (INSPQ).
55. Ali H., Donovan B., Wand H., Read T.R., Regan D.G., Grulich A.E., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
56. Palefsky J.M. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010, 46(4 Suppl.):S12-S19.
57. Parkin D.M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3):S3.11-S3.25.
58. Jit M., Choi Y.H., Laprise J.F., Drolet M., Boily M.C., Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?. Vaccine 2014, 32(26):3237-3242.
59. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.
60. Weinstein M.C., O'Brien B., Hornberger J., Jackson J., Johannesson M., McCabe C., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 2003, 6(1):9-17.
61. Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44.